SCHEMBL3728364

SCHEMBL3728364

CN(C)Cc1cccc(NC(=N)N)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 3/20 0.50
KDM1A O60341 1/20 0.46
RCOR1 Q9UKL0 1/20 0.46
NOS2 P35228 1/20 0.44
GRIN2D O15399 7/20 0.44
GRIN3B O60391 7/20 0.44
GRIN1 Q05586 7/20 0.44
GRIN2A Q12879 7/20 0.44
GRIN2B Q13224 7/20 0.44
GRIN2C Q14957 7/20 0.44
GRIN3A Q8TCU5 7/20 0.44
ROCK2 O75116 2/20 0.43
SIGMAR1 Q99720 4/20 0.42
AURKA O14965 1/20 0.41
RPS6KB1 P23443 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
ITGB3 P05106 1/20 0.40
ITGA2B P08514 1/20 0.40
KIT P10721 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3726618 0.84 HTR6 (0.50) NOS1NOS2GRIN2DGRIN3BGRIN1
SCHEMBL9381846 0.84 KDM1A (0.52) NOS1KDM1ARCOR1NOS2ROCK2
SCHEMBL3597276 0.84 CYP1A2 (0.56) NOS1KDM1ARCOR1NOS2GRIN2D
SCHEMBL7898720 0.81 ITGB3 (0.43) NOS1NOS2GRIN2DGRIN3BGRIN1
SCHEMBL8269124 0.81 SIGMAR1 (0.60) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL6679400 0.80 KDM1A (0.44) NOS1KDM1ARCOR1NOS2GRIN2D
[3-(Hydroxymethyl)Phenyl]Guanidine SCHEMBL1186272 0.80 PRSS1 (0.55) NOS1KDM1ARCOR1NOS2GRIN2D
SCHEMBL28347492 0.80 ITGB3 (0.43) NOS1NOS2GRIN2DGRIN3BGRIN1
SCHEMBL6678310 0.80 LOXL2 (0.55) NOS1NOS2GRIN2DGRIN3BGRIN1
SCHEMBL6679402 0.79 SIGMAR1 (0.51) NOS1NOS2GRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435435-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-01-29 EP disclosed
US-8536180-B2 Pyrimidine inhibitors of kinase activity ABBVIE INC. (US) 2013-09-17 US disclosed
CN-102459265-A Pyrimidine inhibitors of kinase activity ABBOTT LAB 2012-05-16 CN disclosed
WO-2010138575-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 WO disclosed
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY IGF1R, TK1, CDK2 NOS1 2688/4885KDM1A 2140/4885RCOR1 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.